Atara Biotherapeutics (ATRA) Change in Accured Expenses (2013 - 2026)

Atara Biotherapeutics' Change in Accured Expenses history runs 14 years deep, the most recent figure standing at -$642000.0 for Q1 2026.

• Quarterly Change in Accured Expenses fell 118.38% year-over-year to -$642000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.5 million (down 195.5% YoY) and the FY2025 annual result came in at -$5.3 million, up 57.47% from the prior year.
• Change in Accured Expenses was -$642000.0 for Q1 2026 at Atara Biotherapeutics, up from -$796000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $9.6 million in Q4 2022 and bottomed at -$8.7 million in Q1 2023.
• A 5-year average of -$1.3 million and a median of -$1.8 million in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 227.38% — and 2023, when it plunged 1434.39%.
• Atara Biotherapeutics' Change in Accured Expenses stood at $9.6 million in 2022, then tumbled by 130.29% to -$2.9 million in 2023, then grew by 29.3% to -$2.1 million in 2024, then surged by 61.32% to -$796000.0 in 2025, then gained by 19.35% to -$642000.0 in 2026.
• Business Quant data shows ATRA's Change in Accured Expenses at -$642000.0 in Q1 2026, -$796000.0 in Q4 2025, and -$3.1 million in Q3 2025.